Remove tag medicines-pricing
article thumbnail

STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available

STAT

In the latest bid to widen access to medicines, a nonprofit is sending technology and materials for making expensive CAR-T cell therapies to the Brazilian government and an Indian manufacturer that will, in turn, look to provide the treatments available at a fraction of current prices in the U.S.

122
122
article thumbnail

STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps

STAT

In response to controversy, a group of Colorado lawmakers is abandoning a bill that would have required a new state board — which is chartered with setting caps for the cost of medicines — to create exemptions for rare disease drugs. Continue to STAT+ to read the full story…

113
113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ICER updates cost-effectiveness threshold for bluebird, Vertex and CRISPR's dueling sickle cell gene therapies

Fierce Pharma

The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.

92
article thumbnail

STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy

STAT

Kyowa Kirin is paying $16 per share — a nearly 100% premium on Orchard’s Wednesday closing price — in cash, amounting to roughly $390 million. LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in a $400 million deal, the companies said Thursday.

107
107
article thumbnail

STAT+: Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages

STAT

Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies.

Dosage 103
article thumbnail

STAT+: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions

STAT

Such decisions are based on myriad factors, starting with the average $26,500 price tag. But there are other considerations, including the quality of the clinical trial data, side effect concerns, the patient population for which the medicine is approved, and budgetary constraints.

FDA 103
article thumbnail

Haemophilia drug costing $3.5m per dose has been approved

Pharmafile

CSL Behring’s haemophilia B gene therapy has recently been approved by US regulators, however the treatment has an enormous price tag. per dose, the one-off infusion therapy has become the world’s most expensive medicine currently available. Costing $3.5m

72